RxDoctor Payments Data

Jared Routh, MD

Cardiovascular Disease · West Des Moines, IANPI 1659718104

Payments from drug & device makers

$902in general payments, 2019–2025

Across 22 payments — averaging $41.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$589
  • Heartflow, Inc.$119
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$61
  • Novartis$42
  • Cardiva Medical, Inc.$25
  • Boehringer Ingelheim$19
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$79088%
  • Education$11212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$902 in reported general payments places this provider in the 35th percentile of 142 cardiovascular disease providers in Iowa.

See all cardiovascular disease providers in Iowa

Medicare billing

Part B allowed, 2024
$215,715
Medicare patients
1,653
Services billed
3,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban225$199,425
JardianceEmpagliflozin104$88,610
Repatha SureclickEvolocumab44$26,027
XareltoRivaroxaban22$20,039
EntrestoSacubitril/Valsartan23$18,873
Rosuvastatin Calcium223$2,239
Metoprolol Succinate238$2,173
Atorvastatin Calcium129$1,106
Amiodarone Hcl31$1,058
Valsartan29$1,052
Amlodipine Besylate168$964
Bumetanide38$839
Ezetimibe56$829
Diltiazem 24hr Er (La)Diltiazem Hcl15$800
Prasugrel Hcl11$702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$19$88,610104 claims
NovartisEntresto$42$18,87323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 142 cardiovascular disease providers in Iowa.

Other cardiovascular disease in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →